Gold complexes with 2-selenoxo-1,3-dithiole-4,5-dithiolato

DOI: 10.1016/S0277-5387(97)00302-1

Source and publish data:

Polyhedron p. 295 - 298 (1998)

Update date:2022-08-03

Topics:

Authors:

Cerrada, Elena

Laguna, Mariano

Sorolla, Pedro A.

Read Full Text PDF DownLoad Join now for total 90,000,000 free articles

Article abstract of DOI:10.1016/S0277-5387(97)00302-1

The reaction of Na₂dmise (dmise = 2-selenoxo-1,3-dithiole-4,5-dithiolate) with [AuClL] in 1:2 molar ratio affords [Au₂(dmise)L₂] (L = PR₃ or CH₂PPh₃) but in 1:1 ratio in the presence of (NB

Full text of DOI:10.1016/S0277-5387(97)00302-1

Products guided by the article

Product name:Au₂(C₃S₄Se)(P(C₆H₅)3)2

Cas No:201612-30-8

R&D Labs maybe for 201612-30-8

Hebei Think-Do Environment Co., Ltd

website:http://www.thinkdo-environment.com

Contact:0311-86510809-

Address:No 6, Shilian Middle Street, Circular Chemical Industry Park
shanghai payne pharm co.,ltd.

Contact:+86-021-58123769

Address:No.780 of Cailun Road,Zhangjiang Hi-tech Park,Pudong,Shanghai
Beyond Pharmaceutical Co., Ltd

Contact:+86-571-8195-3185

Address:No. 13-1, Liansheng Road, Yuhang District
SuZhou Ascepion Pharmaceuticals, Inc.(expird)

Contact:0512-86881668

Address:Building C,68Xingqing Road,Suzhou,China.
Zhejiang kehong chemical co., ltd

Contact:0086-575-85522000

Address:xiner center RD binhai industrial zone shaoxing zhejiang province P.R.China,312073

Relevant to this article

A calixarene with four peptide loops: An antibody mimic for recognition of protein surfaces

Doi:10.1002/anie.199726801
(1997)
Doi:10.1021/ja01137a001
(1952)
The total synthesis of lipid I

Doi:10.1021/ja016082o
(2001)
An enantioselective synthesis of cis perhydroisoquinoline LY235959

Doi:10.1021/jo9717649
(1998)
Stereocontrol in nickel mediated syntheses of cyclobutabenzenes. The selective preparation of cis and trans derivatives of 7,8-dibromocyclobutabenzene

Doi:10.1016/S0040-4020(97)10219-8
(1998)
(Phenylpiperidinyl)cyclohexylsulfonamides: Development of α_1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS)

Doi:10.1016/j.bmcl.2007.04.098
(2007)

Article Doi